Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the “Debtors”) have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware (“Bankruptcy Court”) and will seek to sell their assets through a court supervised sales process.
Read the full article: Clovis Oncology Files for Chapter 11 Protection //
Source: https://www.businesswire.com/news/home/20221211005087/en/Clovis-Oncology-Files-for-Chapter-11-Protection-and-Enters-into-Agreement-to-Sell-FAP-2286